-+ 0.00%
-+ 0.00%
-+ 0.00%

ORIC® PHARMACEUTICALS ANNOUNCES AGREEMENT WITH CANCER RESEARCH UK TO ADVANCE A POTENTIAL FIRST-IN-CLASS CIP2A-TARGETED THERAPY INTO CLINICAL DEVELOPMENT

Reuters·10/05/2026 20:02:23

Veuillez vous connecter pour afficher les détails des actualités